RT @NEJM: Andrew Hantel, MD, discusses a source of discrimination against some patients in cancer research and care practices. Full intervi….

RT @NEJM: Hantel et al. write that cancer research and care practices that adversely affect people with the Duffy null phenotype are an und….

RT @Jmarksloan: There should be Duffy null specific values for:.-Dose modifications on and off trial.-CTCAE toxicities.-Remission criteria….

Our new article in @JAMANetworkOpen describes cancer trial eligibility and dose-modifications for individuals with Duffy null (DN) phenotype. 77% of trials & 54% of regimens excluded or modified doses for neutrophil counts within the DN reference range.

Excited to share our study on the environmental and downstream human health effects of tele-oncology and decentralized cancer care as an oral abstract @ASCO 2024 and simultaneously published in @JAMAOnc : @DFCIPopSci @DanaFarber.

Grateful to have played a part in this guidance from @ASCO , now live in @JCO_ASCO .

RT @ASH_hematology: A new study in @BloodAdvances highlights the need to address racial and ethnic #clinicaltrial enrollment disparities. R….

RT @BloodAdvances: Article here: Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical….

RT @RyanNipp: Interesting study demonstrates that gait speed correlates with survival but not treatment intensity recommendation in older a….

RT @JAMAOnc: 55% and 26% of US states' crisis standards of care guidelines deprioritized or excluded some patients with cancer during scarc….

RT @UCCancerCenter: Wendy Stock summarizes data presented in exciting session on AML, MDS & CLL prognosis & monitoring biomarkers #ASCO15 h….